Kawasaki Medical School

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Boehringer Ingelheim (Japan)日本5
2. Eli Lilly (Japan)日本3
3. Boehringer Ingelheim (Germany)德国3
4. Kitakyushu City Hospital Organization日本2
5. National Defense Medical College Hospital日本2
6. Tohoku University日本2
7. Tokyo Medical and Dental University日本2
8. Takeda (Japan)日本2

按月发文

逐年被引

最新文献

1. 1
   Long-term safety and effectiveness of vonoprazan as maintenance therapy for reflux esophagitis in Japan: a 12-month post-marketing surveillance studyExpert Opinion on Drug Safety20261
2. 2
   Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance studyExpert Opinion on Drug Safety20234
3. 3
   Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance studyExpert Opinion on Drug Safety20228
4. 4
   Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance studyExpert Opinion on Drug Safety202213
5. 5
   Clinical characteristics and tumor markers in ischemic stroke patients with active cancerInternal and Emergency Medicine202110
6. 6
   IgA Vasculitis in a Lung Cancer Patient During ChemoradiotherapyTherapeutics and Clinical Risk Management20214
7. 7
   Hyperoxemia during resuscitation of trauma patients and increased intensive care unit length of stay: inverse probability of treatment weighting analysisWorld Journal of Emergency Surgery202115
8. 8
   Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesisExpert Opinion on Drug Safety202112
9. 9
   Association of frailty on treatment outcomes among patients with suspected infection treated at emergency departmentsEuropean Journal of Emergency Medicine20218
10. 10
    Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance studyExpert Opinion on Drug Safety201930

高被引文献

1. 1
   Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes MellitusDrug Safety201937
2. 2
   Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance studyExpert Opinion on Drug Safety201930
3. 3
   Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancerTherapeutics and Clinical Risk Management201523
4. 4
   Acute necrotizing encephalopathy in an adult with influenza A infectionTherapeutics and Clinical Risk Management201816
5. 5
   Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patientsExpert Opinion on Drug Safety201716
6. 6
   Hyperoxemia during resuscitation of trauma patients and increased intensive care unit length of stay: inverse probability of treatment weighting analysisWorld Journal of Emergency Surgery202115
7. 7
   Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance studyExpert Opinion on Drug Safety202213
8. 8
   Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesisExpert Opinion on Drug Safety202112
9. 9
   Clinical characteristics and tumor markers in ischemic stroke patients with active cancerInternal and Emergency Medicine202110
10. 10
    Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance studyExpert Opinion on Drug Safety20228

主要发表期刊